Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.

What Was Tested

The paper reports a study of Glucagon, published as an observational study.

To compare the risk of developing kidney outcomes with use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus use of sodium-glucose cotransporter-2 (SGLT2) inhibitors among individuals with diabetes.

A 1:4 propensity-score-matching algorithm was used to compare the changes in eGFR between GLP-1RA and SGLT2 inhibitor users.

Who Took Part

The abstract describes 12,338 individuals taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

In this retrospective observational study, the researchers analysed 12 338 individuals with diabetes who newly initiated SGLT2 inhibitors or GLP-1RAs using data from the JMDC claims database.

The primary outcome was change in the estimated glomerular filtration rate (eGFR), estimated using a linear mixed-effects model.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glomerular Filtration Rate, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Propensity Score and Sodium-Glucose Transporter 2 Inhibitors.

The authors tagged it with the keywords GLP‐1RA, SGLT2 inhibitors and chronic kidney disease.

What This Means in Plain Language

This is an observational study of Glucagon in 12,338 individuals.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page, all human trials.